Manufacturing Challenges In Cancer Vaccine Development
Source: Bioprocess Online
From LNP stability to outsourced manufacturing capacity, there’s no shortage of challenges to developing and manufacturing both viral and RNA-based therapeutic vaccines. In this segment of the Bioprocess Online Live event, guest experts Peter Berglund, chief scientific officer at HDT Bio, Johanna Kaufmann, EVP for oncology at Codagenix, and Robert Georgantas, president and CTO at Providence Therapeutics address those challenges, and our audience’s questions about them.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
This website uses cookies to ensure you get the best experience on our website. Learn more